#1 Clinical Trials Search in Europe

Tafamidis

Tafamidis is an oral medication being studied in clinical trials for the treatment of transthyretin amyloidosis, a rare and serious condition that affects the heart and nervous system. This article summarizes key findings from recent clinical trials evaluating the safety and effectiveness of tafamidis in patients with different forms of transthyretin amyloidosis.

Table of Contents

What is Tafamidis?

Tafamidis is a medication used to treat certain types of heart and nerve conditions. It’s also known by the brand name Vyndaqel[1]. Tafamidis is a specialized drug that works by stabilizing a protein in the body called transthyretin (TTR), which can become unstable and cause problems in some people[2].

What Conditions Does Tafamidis Treat?

Tafamidis is primarily used to treat two main conditions:

  1. Transthyretin Amyloid Cardiomyopathy (ATTR-CM): This is a heart condition where abnormal proteins build up in the heart, making it harder for the heart to work properly[3].
  2. Transthyretin Amyloid Polyneuropathy (ATTR-PN): This is a nerve condition where abnormal proteins affect the nerves, causing problems with sensation and movement[4].

Both of these conditions are caused by problems with the transthyretin protein, which tafamidis helps to stabilize.

How Does Tafamidis Work?

Tafamidis works by binding to the transthyretin protein in the body. This binding helps to stabilize the protein and prevent it from breaking apart and forming harmful deposits in the heart or nerves. By keeping the protein stable, tafamidis can slow down the progression of ATTR-CM and ATTR-PN[2].

Forms and Dosages of Tafamidis

Tafamidis comes in different forms and dosages:

  • Soft gel capsules: These are available in 20 mg and 61 mg strengths[3][5].
  • Tablets: New tablet forms are being developed, including 12.2 mg, 61 mg, and 70 mg strengths[6].

The dosage and form prescribed will depend on the specific condition being treated and the patient’s individual needs. Tafamidis is typically taken once daily[2].

Effectiveness of Tafamidis

Clinical trials have shown that tafamidis can be effective in treating both ATTR-CM and ATTR-PN. In patients with ATTR-CM, tafamidis has been found to:

  • Reduce the risk of death
  • Decrease the frequency of hospitalizations related to heart problems
  • Improve quality of life
  • Increase the distance patients can walk in 6 minutes (a measure of physical function)[2]

For patients with ATTR-PN, tafamidis has shown improvements in nerve function and quality of life[4].

Potential Side Effects

While tafamidis is generally well-tolerated, like all medications, it can have side effects. Common side effects may include:

  • Diarrhea
  • Urinary tract infections
  • Dizziness
  • Headache

It’s important to note that not everyone experiences side effects, and your doctor will monitor you closely while you’re taking tafamidis[3].

Ongoing Research on Tafamidis

Researchers continue to study tafamidis to better understand its effects and to develop improved formulations. Current areas of research include:

  • Long-term safety studies to understand the effects of tafamidis over extended periods[3].
  • Development of new tablet forms that may be easier for some patients to take[6].
  • Studies on how tafamidis interacts with other medications, such as statins used to lower cholesterol[1].
  • Investigations into the effectiveness of different doses of tafamidis[2].

These ongoing studies aim to improve treatment options and outcomes for patients with ATTR-CM and ATTR-PN.

Aspect Details
Main Conditions Studied Transthyretin Amyloid Polyneuropathy (ATTR-PN), Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Dosages 20 mg, 61 mg, 80 mg daily oral doses
Key Outcome Measures TTR stabilization, Neuropathy Impairment Score, 6-Minute Walk Test, Quality of Life scores, Mortality, Cardiovascular-related hospitalizations
Safety Profile Monitored through adverse events, vital signs, ECG, laboratory tests
Trial Durations Typically 12-30 months
Populations Patients with ATTR-PN, ATTR-CM, and healthy volunteers for pharmacokinetic studies

FAQ

  • What is tafamidis used to treat? Tafamidis is being studied to treat transthyretin amyloidosis, which includes conditions like transthyretin amyloid polyneuropathy (ATTR-PN) and transthyretin amyloid cardiomyopathy (ATTR-CM). These are rare diseases caused by abnormal buildup of transthyretin protein in organs and tissues.
  • How does tafamidis work? Tafamidis works by stabilizing the transthyretin protein, which helps prevent it from breaking apart and forming harmful amyloid deposits in the body. This stabilizing effect is measured in clinical trials as 'TTR stabilization'.
  • What doses of tafamidis are being studied? Various doses are being evaluated in clinical trials, including 20 mg, 61 mg, and 80 mg daily oral doses. Some trials compare different doses to determine the optimal amount.
  • What are the main outcomes measured in tafamidis clinical trials? Key outcomes include changes in neurological impairment scores, quality of life measures, walking ability, heart function tests, TTR stabilization, and rates of hospitalization and mortality. Safety and side effects are also closely monitored.
  • How long do the clinical trials for tafamidis typically last? The duration varies, but many of the trials last between 12-30 months to evaluate both short-term and longer-term effects of the medication. Some trials include follow-up periods to assess outcomes over time.

Ongoing Clinical Trials on Tafamidis

  • Study on How Tafamidis is Absorbed in the Blood of Healthy Adults with Transthyretin Amyloid Cardiomyopathy

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Belgium

  • Study on the Effects of Tafamidis in Patients with Transthyretin Cardiac Amyloidosis

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Portugal

Glossary

  • Transthyretin (TTR): A protein in the blood that transports thyroid hormone and vitamin A. Abnormal forms of this protein can build up in organs, causing amyloidosis.
  • Amyloidosis: A group of diseases characterized by abnormal buildup of specific proteins in organs and tissues, interfering with normal function.
  • ATTR-PN: Transthyretin Amyloid Polyneuropathy, a form of amyloidosis that primarily affects the nervous system.
  • ATTR-CM: Transthyretin Amyloid Cardiomyopathy, a form of amyloidosis that primarily affects the heart.
  • TTR stabilization: A measure of how well tafamidis prevents the transthyretin protein from breaking apart, which is believed to be its main mechanism of action.
  • Neuropathy Impairment Score (NIS): A clinical measure of nerve function used to assess the severity of polyneuropathy.
  • 6-Minute Walk Test (6MWT): A test that measures the distance an individual can walk in 6 minutes, used to assess functional capacity.
  • NT-proBNP: N-terminal pro-brain natriuretic peptide, a blood marker used to assess heart failure severity.
  • KCCQ: Kansas City Cardiomyopathy Questionnaire, a tool used to measure quality of life in heart failure patients.
  • Bioavailability: The proportion of a drug that enters the circulation when introduced into the body and is able to have an active effect.

References

  1. https://clinicaltrials.gov/study/NCT04253353
  2. https://clinicaltrials.gov/study/NCT01994889
  3. https://clinicaltrials.gov/study/NCT02791230
  4. https://clinicaltrials.gov/study/NCT04828993
  5. https://clinicaltrials.gov/study/NCT06705569
  6. https://clinicaltrials.gov/study/NCT06273839